

24th Scientific Meeting of the International Society of Cardiovascular Pharmacotherapy (ISCP)

Lugano – Switzerland

Thursday, May 9th and Friday, May 10th 2019

**Organized in collaboration with
the Working Group on Cardiovascular Pharmacotherapy
(European Society of Cardiology),
the Swiss Society of Cardiology (SSC) and
the Swiss Atherosclerosis Association
French Society of Cardiology**

Preliminary Programme

Course Directors:

Prof Augusto Gallino, Bellinzona CH
Prof Juan Carlos Kaski, London GB
Prof Alexandre Fredenrich, Bellinzona CH/Nice FR
Prof Heinz Drexel, Feldkirch AT

Version 07.05.2018/**11.01.2019**

Thursday, May 9th 2019

08.10 – 08.15 BRIEF OPENING OF THE MEETING	
Paolo Ferrari, Chief Medical Officer, Ente Ospedaliero Cantonale	
08.15 – 09.35	WORLD EPIDEMICS – Joint Session with ESC Working Group on Cardiovascular Pharmacotherapy Chairpersons: Thomas Kahan (Stockholm, SE), Antoni Martinez-Rubio (Barcelona, ES), Hector Ventura (New Orleans, US), Luca Gabutti (Bellinzona, CH)
08.15 – 08.30	Dyslipidemia – new challenges and how to achieve targets Heinz Drexel (Feldkirch, AT)
08.30 – 08.45	Hypertension – the many faces of systemic hypertension Celso Amodeo (Sao Paulo, BR)
08.45 – 09.00	The management of patients with diabetes and heart failure: the start of a new era? Felipe Martinez (Cordoba, AR)
09.00 – 09.15	Obesity after smoking cessation – rationale of a complex interplay Koji Hasegawa (Kyoto, JP)
09.15 – 09.35	Discussion
09.35 – 10.35	A CHANGING PARADIGM IN MANAGEMENT OF DYSLIPIDEMIA Chairpersons: Koji Hasegawa (Kyoto, JP), Arnold von Eckardstein (Zurich, CH), Alexandre Fredenrich (Bellinzona, CH/Nice, FR), Heinz Drexel (Feldkirch, AT), Brenno Balestra (Mendrisio, CH)
09.35 – 09.50	The discovery of PCSK9 Catherine Boileau (Paris, FR)
09.50 – 10.05	Opportunities and barriers for the successful clinical utilisation of PCSK9 Michel Farnier (Dijon, FR)
10.05 – 10.20	PCSK9 – Effects beyond LDL Lowering Alberico L. Catapano (Milano, IT)
10.20 – 10.35	Discussion
10.35 – 11.05	Coffee Break
11.05 – 12.20	ANTI-INFLAMMATORY TREATMENT IN CORONARY ARTERY DISEASE Chairpersons: Filippo Crea (Rome, IT), Giuseppe Vassalli (Lugano, CH), Alberto Lorenzatti (Cordoba, AR), Konstantinos Koskinas (Bern, CH)
11.05 – 11.20	The rationale for anti-inflammatory treatment Peter Libby (Boston, US)
11.20 – 11.35	“ <i>in vivo</i> ” evidence of the inflammatory hypothesis in humans Augusto Gallino (Bellinzona, CH)

11.35 – 11.50	The clinical evidence: targeting interleukin-1 β : the CANTOS trial Luigi M. Biasucci (Rome, IT)
11.50 – 12.05	A word of caution Juan Carlos Kaski (London, GB)
12.05– 12.20	Discussion

12.20 – 13.20 Satellite Working Lunch Session organized by AMGEN

12.20 – 13.20 Lunch

13.20 – 14.10	MEDICAL VS INVASIVE TREATMENT STRATEGIES IN STABLE CORONARY ARTERY DISEASE: DEBATE SESSION Chairpersons: Koji Hasegawa (Kyoto, JP), Edgardo Escobar (Santiago, CL), Marco Moccetti (Lugano, CH), Claudio Ceconi (Ferrara, IT)
13.20 – 13.35	Too many patients in Europe undergo endovascular treatment for stable coronary artery disease instead of optimal medical treatment – review of recent evidence Filippo Crea (Rome, IT)
13.35 – 13.50	Missed opportunities for successful myocardial revascularisation in stable coronary artery disease Stefan Windecker (Bern, CH)
13.50 – 13.55	Rebuttal Filippo Crea (Rome, IT)
13.55 – 14.00	Rebuttal Stefan Windecker (Bern, CH)
14.00 – 14.10	Discussion

14.10 – 15.10	EMERGING INDICATIONS FOR NEW ORAL ANTICOAGULATION IN STABLE CORONARY ARTERY DISEASE Chairpersons: Gheorghe Dan (Bucharest, RO), Juerg H. Beer (Baden, CH), Antoni Martinez-Rubio (Barcelona, ES), Roberto Corti (Zurich, CH)
14.10 – 14.25	Rivaroxaban; from research to medicine Elisabeth Perzborn (Wuppertal, DE)
14.25 – 14.40	NOACs in acute coronary syndrome and after coronary stent in patients with atrial fibrillation Giovanni B. Pedrazzini (Lugano, CH)
14.40 – 14.55	Advances in anticoagulant therapies; from Aspirin to NOACs Salim Yusuf (Hamilton, CA)
14.55 – 15.10	Discussion

15.10 – 15.40 Coffee break

15.40 – 16.25	ANTITHROMBOTIC TREATMENT IN ACUTE CORONARY ARTERY DISEASE IN THE WORLD OF EMERGING STENTS Chairpersons: Felipe Martinez (Cordoba, AR), Doreen Tan (Singapore , SGP), Daniel Suerder (Lugano, CH), Pablo Avanzas (Oviedo, SP)
---------------	--

15.40 – 15.55	State of the art of antithrombotic prevention Gilles Montalescot (Paris, FR)
15.55 – 16.10	Will emerging stents simplify antithrombotic treatment? Marco Roffi (Geneva, CH)
16.10 – 16.25	Discussion

16.25 – 17.20	PCSK-9 Inhibition: Insights from the ODYSSEY OUTCOMES Trial Chairpersons: Heinz Drexel (Feldkirch, AT), Alvaro S. Liprandi (Buenos Aires, AR), Stefan Windecker (Bern, CH) A SANOFI SYMPOSIUM
16.25 – 16.40	Effect of Alirocumab on cardiovascular events and all-cause mortality (Christian Mueller (Basel, CH))
16.40 – 16.55	Advances in targeting LDL and Lp(a)- Causal Risk Factors for Atherosclerosis Peter Libby (Boston, US)
16.55 – 17.10	Patients to consider for Aliricumab treatment Alberico L. Catapano (Milano, IT)
17.10 – 17.20	Discussion

17.20 – 17.50	DISTINGUISHED EUGENE BRAUNWALD LECTURE Chairpersons: Augusto Gallino (Bellinzona, CH), Juan Carlos Kaski (London, GB), Filippo Crea (Rome, IT)
17.20 – 17.40	The Inclisiran (RNAi of PCSK9) trial: an avenue for postponing CAD until the age of 100? Eugene Braunwald (Boston, US)
17.40 – 17.50	Discussion

17.50 – 18.20	NEUFELD LECTURE Chairpersons: Juan Carlos Kaski (London, GB), Tiziano Moccetti (Lugano, CH), Koji Hasegawa (Kyoto, JP), Augusto Gallino (Bellinzona, CH)
	The Polypill: A simple, inexpensive approach to reduce mortality and morbidity worldwide Salim Yusuf (Hamilton, CA)

Friday, May 10th 2019

08.15 – 09.30	ATRIAL FIBRILLATION Chairpersons: Geneviève Derumeaux (Créteil, FR), Giuseppe Calveri (Varese, IT), Andrea Menafoglio (Bellinzona, CH)
08.15 – 08.30	Antiarrhythmic drugs for atrial fibrillation – State of the art Gheorghe Dan (Bucharest, RO)
08.30 – 08.45	Advances in curative approaches Maria Luce Caputo (Lugano, CH)
08.45 – 09.00	Neurocognitive function in atrial fibrillation and anticoagulation: lessons from the Swiss atrial fibrillation cohort study Stefan Osswald (Basel, CH)
09.00 – 09.15	Stroke prevention: state of the art Antoni Martinez-Rubio (Barcelona, ES)
09.15 – 09.30	Discussion
09.30 – 10.10	CHRONIC HEART FAILURE: A PARADIGM SHIFT Chairpersons: Georg Noll (Zurich, CH), Giuseppe Rosano (London, GB), Hector Ventura (New Orleans, US)
09.30 – 09.45	A paradigm shift in the treatment of heart failure Karl Swedberg (Gothenburg, SE)
09.45 – 10.00	Devices for management of heart failure Frank Ruschitzka (Zurich, CH)
10.00 – 10.10	Discussion
10.10 – 10.40	Coffee Break
10.40 – 11.15	KEY LECTURE – ACUTE HEART FAILURE Chairpersons: Basil Lewis (Haifa, IL), Thomas Suter (Bern, CH), Maurizio Volterrani (Rome, IT), Marcello Di Valentino (Bellinzona, CH)
10.40 – 11.00	Acute heart failure: death risk higher than heart attack but care lags 30 years behind Christian Mueller (Basel, CH)
11.00 - 11.15	Discussion
11.15 – 11.45	STATE OF THE ART LECTURE Chairpersons: Thomas Kahan (Stockholm, SE), Ferenc Follath (Lugano, CH), Juan Carlos Kaski (London, GB), Agewall Stefan (Oslo, NO)
11.15 – 11.45	Pharmacotherapy of the future: From Molecules to genetic tools Thomas Luescher (London UK, Zurich, CH)

11.45 – 12.45	NEW ANTIDIABETIC DRUGS IMPROVE CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH CORONARY ARTERY DISEASE AND DIABETES A Boehringer Ingelheim (Schweiz) GmbH Symposium Chairpersons: Alexandre Fredenrich (Bellinzona, CH/Nice, FR), Heinz Drexel (Feldkirch, AT), Michael Zellweger (Basel, CH), Francesco Paneni (Rome IT, Zurich CH)
11.45 – 12.00	SGLT2 inhibitors: a change of paradigm in the treatment of cardiac failure in patients with Type 2 diabetes Philippe van de Borne (Brussels, BE)
12.00 -- 12.15	Beyond CVOT trials: SGLT2 inhibitors in Heart failure patients without diabetes Francesco Paneni (Rome IT, Zurich CH)
12.15 – 12.30	Emerging REAL-world Data versus clinical randomized trials and Type 2 diabetes guidelines Heinz Drexel (Feldkirch, AT)
12.30 – 12.45	Discussion
12.45 – 13.15	KEY LECTURE Chairpersons: Heinz Drexel (Feldkirch, AT), Philippe van de Borne (Brussels, BE), Marco Pons (Lugano, CH)
12.45 – 13.05	Cardiovascular effects of incretin-based therapies: lessons from the trials testing GLP1 RAs Aldo Maggioni (Firenze, IT)
13.05 – 13.15	Discussion
13.15 – 14.00	A Sanofi Symposium THE EMERGING ROLE OF PCSK9 INHIBITORS AFTER ACS Chairpersons: Alberico L. Catapano (Milano, IT), Alberto Lorenzatti (Cordoba, AR), Giorgio Nosedà (Mendrisio, CH), Heinz Drexel (Feldkirch, AT)
13.15 – 13.30	Tackling the residual risk Alvaro S. Liprandi (Buenos Aires, AR)
13.30 – 13.45	The emerging role of PCSK9 inhibitors after an acute coronary event: successful return after an Odyssey François Mach (Geneva, CH)
13.45 – 14.00	Discussion
13.15 – 14.15	Lunch

14.15 – 15.15	ARTERIAL HYPERTENSION Chairpersons: Georg Noll (Zurich, CH), Celso Amodeo (Sao Paulo, BR), Franco Muggli (Lugano, CH),
14.15 – 14.30	The hypertension paradox – more uncontrolled disease despite improved therapy Gianfranco Parati (Milano, IT)
14.30 – 14.45	Target blood pressure in patients at high cardiovascular risk Thomas Kahan (Stockholm, SE)
14.45 – 15.00	Antihypertensive treatment in the very elderly Georg Noll (Zuerich,CH)
15.00 – 15.15	Discussion
15.15 – 15.40	ASPIRIN IN PRIMARY PREVENTION: A PARADIGM CHANGE? Chairpersons: Mauro Capoferri (Chiasso, CH)
15.15 – 15.30	Lessons from the ASPREE trial John McNeil (Melbourne, AU)
15.30 – 15.40	Discussion
15.40 – 16.20	VENTRICULAR AND ATRIAL REMODELING – THE ROAD TO HEART FAILURE AND STROKE: FUTURE APPROACHES. A joint Session with the French Society of Cardiology Chairpersons: Antoni Martinez-Rubio (Barcelona, ES), Gheorghe Dan (Bucharest, RO), Denis Cokkinos (Athens, GR)
15.40 – 15.55	Cardiac remodeling in metabolic cardiomyopathy Geneviève Derumeaux (Créteil, FR)
15.55 – 16.10	Left ventricular architecture, long-term reverse remodeling and clinical outcome: lessons from the REVERSE trial Jean-Claude Daubert (Rennes, FR)
16.10 – 16.20	Discussion
16.20 – 16.45	ISCP AWARDS Augusto Gallino (Bellinzona, CH), Juan Carlos Kaski (London, GB),
16.20 – 16.30	Brief historical closing remarks Wilhelm Rutishauser
16.30 – 16.40	ISCP Posters Awards
16.40 -16.45	Announcement of the 2020 ISCP annual meeting Miami Hector Ventura
16.45	End of the Meeting